Introduction
============

High treatment-associated complication rates remain an important challenge to the success of allogeneic hematopoietic stem cell transplantation (alloSCT). A common mechanism of the major infectious- and non-infectious complications after alloSCT, such as graft-*versus*-host disease (GvHD) and sepsis, is severe inflammation. Critical to excess inflammation after alloSCT are host biomolecules termed 'endogenous danger signals', which can initiate and maintain non-infectious inflammatory responses by acting as pro-inflammatory mediators.^[@b1-1051977],[@b2-1051977]^ One such molecule is uric acid. During conditioning for alloSCT, uric acid is released from injured cells and reduced renal clearance may contribute to high uric acid serum levels.^[@b3-1051977],[@b4-1051977]^ Uric acid acts as a danger signal by enhancing T-cell responses *via* activation of the NOD-like receptor protein (NLRP) 3 inflammasome.^[@b5-1051977],[@b6-1051977]^ A pre-clinical study has provided basic evidence on the regulation of GvHD by uric acid *via* Nlrp3 inflammasome--mediated IL-1 production.^[@b7-1051977]^ The significance of uric acid for alloSCT outcome has been underlined by results from a pilot study reporting reduced incidence of acute GvHD in patients undergoing alloSCT after depletion of uric acid using urate oxidase.^[@b8-1051977]^

Based on these results, and because uric acid is a routine laboratory parameter assessed in patients undergoing alloSCT, there is a strong rationale to investigate the use of uric acid as a biomarker and possibly as a therapeutic target during alloSCT. To study the role of uric acid levels in alloSCT, the Transplant Complications Working Party (TCWP) of the European Society for Blood and Marrow Transplantation (EBMT) performed a prospective, multi-center, non-interventional study. We hypothesized that a high uric acid level prior to alloSCT is an independent risk factor for increased mortality and for the development of severe acute GvHD.

Methods
=======

Data source, study design and data collection
---------------------------------------------

We asked EBMT centers performing more than 50 alloSCT per year if they were willing to participate in this prospective study. Twenty centers in ten countries agreed to participate. Data collection for the EBMT registry was approved by the institutional review board and/or Ethics Committee in all centers. Data were prospectively collected between August, 2014 and February, 2018. Consecutive alloSCT recipients with acute leukemia, lymphoma or myelodysplastic syndrome (MDS) receiving a first matched sibling alloSCT from peripheral blood, regardless of conditioning, were eligible, provided they had signed an informed consent document that permitted sharing of clinical data according to national rules. Basic data on patient and disease characteristics as well as longer term follow-up was taken from minimal essential data (MED-A) forms, which are submitted from all consecutive patients to the central EBMT registry. In addition, we designed registration and MED-B/C forms that were prospectively collected and specific to this study (see the *Online Supplementary Materials and Methods*). The MED-B/C form contained detailed information on uric acid serum levels prior to alloSCT, patient characteristics, infectious- as well as non-infectious complications, GvHD staging, morbidity and mortality. Uric acid levels were determined at the time of hospital admission for alloSCT directly before the start of conditioning therapy. Treatment teams completed the specific forms at the time of registration and at day +100 after alloSCT.

Endpoints and statistical analyses
----------------------------------

Patient, disease, and transplant-related characteristics for the two cohorts (uric acid levels prior to alloSCT above median / uric acid levels below median) were compared by using 2 statistics for categorical variables and the Mann-Whitney test for continuous variables. The primary endpoint was the incidence of acute GvHD. Secondary endpoints were relapse incidence (RI), non-relapse mortality (NRM), overall survival (OS), progression free survival (PFS) and the incidence of chronic GvHD. PFS was defined as survival with no evidence of relapse or progression. RI was defined as the probability of having had a relapse during follow-up time. Death without experiencing a relapse was a competing event. NRM was defined as death without evidence of relapse or progression. OS was defined as the time from alloSCT to death, regardless of the cause. Acute GvHD was graded according to the modified Seattle-Glucksberg criteria^[@b9-1051977]^ and chronic GvHD according to the revised Seattle criteria.^[@b10-1051977]^ Cumulative incidence was used to estimate the endpoints of NRM, RI, acute and chronic GvHD to accommodate for competing risks. To study acute and chronic GvHD, we considered relapse and death to be competing events. Probabilities of OS and PFS were calculated using the Kaplan-- Meier method. Univariate analyses were done using the Gray test for cumulative incidence functions and the log rank test for OS and PFS. A Cox proportional hazards model was used for multivariate regression. All variables differing significantly between the two groups or factors associated with one outcome in univariate analysis were included in the Cox model. The following variables entered the multivariate models as possible confounders: age, sex mismatch between recipient and donor, diagnosis, disease status, Karnofsky score, number of CD34 cells given, intensity of conditioning (EBMT definition: myeloablative conditioning (MAC) was defined as total body irradiation (TBI) \>6 Grey or oral busulfan \>8 mg/kg or intravenous busulfan \>6.4 mg/kg), type of GvHD prophylaxis, ATG use, time from diagnosis to transplant, year of transplant and CMV status. As the number of variables was too high regarding the number of events, a stepwise selection using Akaike information criterion (AIC) was run for all the confounding factors. The difference between the two cohorts was then assessed in the final selected model.

Results were expressed as the hazard ratio (HR) with the 95% confidence interval (95% CI). Proportional hazards assumptions were checked systematically for all proposed models using the Grambsch-Therneau residual-based test. All tests were two-sided. The type I error rate was fixed at 0.05 for the determination of factors associated with time-to-event outcomes. Statistical analyses were performed in November 2018 with R 3.4.2 (R Core Team (2017). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL *<https://www.R-project.org/>*.)

Results
=======

Patients, transplant characteristics and uric acid measurement
--------------------------------------------------------------

The entry criteria for analysis of primary and secondary endpoints were fulfilled in 386 patients. We used the last uric acid serum level that was masured in the individual patients before start of conditioning. The median time point of measurement was three days before start of conditioning. The range was between 0 days (morning before start of conditioning) to 22 days before conditioning. The main patients and transplant characteristics that were included in the analysis of OS are described in [Table 1](#t1-1051977){ref-type="table"}. Most parameters were balanced between the two cohorts. However, a higher percentage of sex mismatch transplants in the direction of female donor to male recipient was observed in the group of patients with uric acid above median before alloSCT. The frequency of patients with reduced-intensity conditioning (RIC) *versus* myeloablative conditioning (MAC) did not differ significantly between the high uric acid group and the low uric acid group (*P*=0.077). When looking exclusively at TBI (*P*=0.59) or by mixing conditioning intensity and TBI (MAC/Chemo *vs*. MAC/TBI *vs*. RIC: *P*=0.20), no statistically significant difference could be observed.

###### 

Patient characteristics.

![](1051977.tab1)

Incidence of acute and chronic GvHD
-----------------------------------

In the present study, the incidence of acute GvHD grades II--IV and grades III--IV in the whole population at 100 days were 25% and 11%, respectively. We observed no significant differences in the frequency of clinically significant acute GvHD grades II--IV in univariate (HR 1.2, 95% CI: 0.8--1.9, *P*=0.4) and multivariate (HR 1.5, 95% CI: 1.0--2.4, *P*=0.08) analysis comparing the high-*versus* the low uric acid cohorts. ([Table 2](#t2-1051977){ref-type="table"} and [Table 3](#t3-1051977){ref-type="table"}). We found no significant differences in the frequency of acute GvHD grades III--IV in univariate (HR=1.8, 95% CI: 0.9--3.4, *P*=0.08) and multivariate (HR 1.7, 95% CI: 0.9--3.2, *P*=0.11) analysis in alloSCT recipients with uric acid levels above cut-off before transplantation *versus* those with low uric acid levels ([Table 2](#t2-1051977){ref-type="table"} and [Table 3](#t3-1051977){ref-type="table"}).

###### 

Univariate global comparison of acute graft-*versus*-host disease shown at day +100 after allogeneic stem cell transplantation.
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###### 

Multivariate global comparison.
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In the whole population, the incidence of chronic GvHD at one year and two years was 27% and 40%, respectively. The incidence of severe chronic GvHD at 1 year and 2 years was 18% and 24%, respectively. We observed no differences in incidence and severity of chronic GvHD between the two cohorts ([Table 3](#t3-1051977){ref-type="table"} and [Table 4](#t4-1051977){ref-type="table"}). The chronic GvHD incidence was significantly lower in alloSCT recipients receiving anti-T-cell globulin (ATG) as part of the conditioning regimen (ATG, HR 0.25 95% CI: 0.13--0.5, *P*\<0.0001).

###### 

Univariate global comparison of overall survival, non-relapse mortality, relapse incidence as well as chronic graft-*versus*-host disease incidence and severity at one year after allogeneic stem cell transplantation.
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Survival endpoints
------------------

The median follow-up time was 15.2 months (95% CI: 13.1--17.0) and OS in the whole population at 1 year was 74%. We found, that OS and PFS of alloSCT recipients with uric acid levels above cut-off, measured before start of conditioning, were significantly shorter compared with the low uric acid cohort ([Figure 1A](#f1-1051977){ref-type="fig"}, OS univariate HR 2.4, 95% CI: 1.6--3.7, *P*\<0.001; multivariate HR 2.8, 95% CI: 1.7--4.7, *P*\<0.0001) ([Figure 1B](#f1-1051977){ref-type="fig"}, PFS univariate HR 2.0, 95% CI: 1.1--3.7, *P*=0.02; multivariate HR 2.7, 95% CI: 1.4--5.0, *P*=0.003). Non-relapse mortality was significantly increased in alloSCT recipients with high uric acid levels prior to start of conditioning ([Figure 2A](#f2-1051977){ref-type="fig"}, univariate HR 2.0, 95% CI: 1.1--3.7, *P*=0.02; multivariate HR 2.7, 95% CI: 1.4--5.0, *P*=0.003). Multivariate as well as univariate analyses are shown in [Table 3](#t3-1051977){ref-type="table"} and [Table 4](#t4-1051977){ref-type="table"}. We conclude that serum uric acid levels prior to alloSCT are an independent risk factor for mortality.

![Survival at one year after allogeneic stem cell transplantation. Overall survival (OS) (A) and progression free survival (PFS) (B) after allogeneic stem cell transplantation (alloSCT) in cohorts according to uric acid serum levels prior to alloSCT: with high uric acid serum levels (blue line), patients with low uric acid levels (red line).](1051977.fig1){#f1-1051977}

![Non-relapse mortality, relapse incidence and infection-related mortality at one year after allogeneic stem cell transplantation. Incidence of non-relapse mortality (NRM) (A), relapse incidence (RI) (B) and infection-related mortality (C) after allogeneic stem cell transplantation (alloSCT) in cohorts according to uric acid serum levels prior to alloSCT: patients with high uric acid serum levels (blue line), patients with low uric acid levels (red line).](1051977.fig2){#f2-1051977}

At the last follow-up 29.3% of the patients were dead (49.6% from relapse, 45.2% alloSCT-related causes and 2.6% from other causes). The causes of death in patients without relapse were mainly due to infection. A descriptive analysis of the causes of death is given in [Table 5](#t5-1051977){ref-type="table"}.

###### 

Causes of death in both cohorts.
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Incidence of infections
-----------------------

We first looked at the incidence of infections in both cohorts and found no significant differences (multivariate HR 0.8, 95% CI: 0.6--1.1, *P*=0.4). We than looked at infection-related mortality and found a significant higher number of infection-related deaths in the high uric acid group ([Figure 2C](#f2-1051977){ref-type="fig"}, multivariate HR 2.6, 95% CI: 1.2-5.2, *P*=0.01).

Incidence of relapse
--------------------

Since uric acid is known to be released from malignant tumours, we were interested in a possible connection of uric acid levels and disease relapse. We found that the relapse incidence in all patients at 1 year was 13%. The relapse incidence was moderately increased in the cohort with higher uric acid levels ([Figure 2B](#f2-1051977){ref-type="fig"}, [Table 3](#t3-1051977){ref-type="table"} and [Table 4](#t4-1051977){ref-type="table"}, univariate HR 1.6, 95% CI: 1.0--2.5; *P*=0.09; multivariate HR 1.6, 95% CI: 1.0--2.5, P=0.04).

Discussion
==========

This prospective study identifies uric acid levels, taken before start of conditioning therapy, as a laboratory biomarker to predict mortality after alloSCT.

In animal experiments and in a clinical pilot study the depletion of uric acid with rasburicase led to a reduced frequency of severe GvHD.^[@b7-1051977],[@b8-1051977]^ Therefore, our initial hypothesis was to primarily find an association between uric acid with acute GvHD and then secondarily with NRM. However, we found a strong positive association of uric acid levels with mortality after alloSCT whereas the association between uric acid levels and acute GvHD incidence was not statistically significant. One of the reasons could be the low incidence of GvHD in our cohort due to the patient characteristics of human leukocyte antigen (HLA)-identical sibling transplant with a high proportion of anti-thymocyte globulin (ATG) use. The use of *in vivo* T-cell depletion with ATG in HLA-identical sibling alloSCT in European centres increased recently.^[@b11-1051977]^ This trend is reflected by a higher frequency of ATG use in the present study (41--46%) than we had initially expected. Another likely reason is a hyperinflammatory status connected to high uric acid levels not restricted to acute GvHD with a negative impact on different relevant clinical situations after alloSCT, such as sepsis^[@b12-1051977]^ and adult respiratory distress syndrome (ARDS).^[@b13-1051977]^ This view is supported by our observation that death due to both infectious and non-infectious complications after alloSCT was increased in patients with high uric acid levels. Interestingly, an association of uric acid levels with decreased solid organ transplant survival has been described further underlining the significance of uric acid for transplantation biology.^[@b14-1051977],[@b15-1051977]^ Our study extends these findings to the setting of alloSCT.

Our study contradicts results from a previous retrospective single centre study, which did not show any significant association of uric acid levels prior to transplantation to mortality after alloSCT.^[@b16-1051977]^ Differences in study designs between the current larger, multicentre and prospective study *versus* the already published smaller, single centre and retrospective study may be the reason for the differing results.

A limitation of this clinical study is the lack of mechanistic insight on the role of uric acid in development of complications after alloSCT. The study design did not allow the investigation of whether the impaired outcome in the high urid acid cohort is due to an active role of uric acid in causing inflammation or whether it is because uric acid primarily is a surrogate biomarker reflecting a hyperinflammatory status and/or activity of the underlying malignancy. However, we found no significant differences regarding the disease status as well as disease risk index (DRI) (complete remission \[CR\] *vs*. non-CR) in between the two groups (high uric acid *vs*.low uric acid). In addition there were no significant differences in the performance status as well as the alloSCT-CI in between the two groups. This data is no proof, but rather points in the direction that high uric acid values were not merely a reflection of advanced disease or increased comorbidity in our study.

A further limitation of our results is that our patient population was restricted to alloSCT from HLA-identical sibling donors. We are therefore unable to draw definite conclusions from these results regarding the association of uric acid levels with outcome in matched unrelated donor alloSCT or in haploidentical alloSCT, which are increasingly used. Another limitation is the incomplete under-standing of the effects of uric acid on post alloSCT immunity. While previous studies showed that uric acid leads to a inflammatory status in leukocytes and our results demonstrate impaired survival in alloSCT recipients with uric acid levels above median, it may be premature to conclude that uric acid is a negative factor at any time around alloSCT. There are clinical situations where immune activation is necessary and desired -- e.g. in anti-infectious and anti-tumor immunity. The impact of depleting uric acid on immune activity in these situations remains to be deter-mined. In addition, it is possible that uric acid is involved in immune reconstitution as it has been suggested recently that changes in uric acid serum levels can indicate incipient or remaining immunological activity after SCT or induction therapy in patients with hematologic malignancies.^[@b17-1051977]^

In conclusion, this study supports the use of serum uric acid levels as biomarker for alloSCT outcome.
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